Advances in functional assays for high-throughput screening of ion channels targets

Expert Opinion on Drug Discovery

Volumn 5, Issue 10, 2010, Pages 995-1006

  Trivedi, Shephali ^a   Liu, Jay ^a   Liu, Ruifeng ^a   Bostwick, Robert ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Calcium channels; Ion channels; Ion flux assays; Lithium flux assay; Potassium channels; Rubidium flux assay; Sodium channels

Indexed keywords

CALCIUM CHANNEL; CHLORIDE CHANNEL; ION CHANNEL; POTASSIUM CHANNEL; SODIUM CHANNEL;

ARTIFACT; ATOMIC ABSORPTION SPECTROMETRY; COST; DRUG DETERMINATION; DRUG TARGETING; EVALUATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUNCTIONAL ASSESSMENT; HIGH THROUGHPUT SCREENING; ION TRANSPORT; MEDICAL TECHNOLOGY; MEMBRANE POTENTIAL; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW;

EID: 77956800503     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.513377     Document Type: Review

References (40)

1. Wickenden A. K+ channels as therapeutic drug targets. Pharmacol Ther 2002;5:157-182
2. Drews J. Drug discover: a historical perspective. Science 2000;287:1960-1964
3. Venter C, Adams MD, Myers EW, et al. The sequence of human genome. Science 2001;291:1304-1351
4. Davies NP, Hanna MG. The skeletal muscle channelopathies: distinct entities and overlapping syndromes. Curr Opin Neurol 2003;16:559-568
5. Mulley JC, Scheffer IE, Petrou S, Berkovic SF. Channelopathies as a genetic cause of epilepsy. Curr Opin Neurol 2003;16:171-176
6. Pietrobon D. Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 2002;25:31-50
7. Kullmann DM. The neuronal channelopathies. Brain 2002;125:1177-1195
8. Hubner CA, Jentsch TJ. Ion channel diseases. Hum Mol Genet 2002;11:2435-2445
9. Abt M, Lim Y, Sacks J, et al. A sequential approach for identifying lead compounds in large chemical databases. Stat Sci 2001;16:154-168
10. Dai GE, Haedo RJ, Warren VA, et al. A high-throughput assay for evaluating state dependence and subtype selectivity of CaV2 calcium channel inhibitors. Assay Drug Dev Technol 2008;6(2):195-212
11. Mattheakis LC, Sayvchenko A. Assay technologies for screening ion channel targets. Curr Opin Drug Discov Devel 2001;1:124-134
12. Rudiger R, Mongillo M, Rizzuto R, Pozzan T. Looking forward to see calcium. Nat Rev Mol Cell Biol 2003;4:579-586
13. Brini M, Marsault R, Bastianutto C, et al. Transfected Aequorin in the measurement of cytosolic Ca2+ concentration([Ca2+]C). J Biol Chem 1995;270:9896-9903
14. Maeda A, Nishimura S, Kameda K, et al. Generation of cell transfectants expressing cardiac calcium ion channel and calcium indicator protein aequorin. Anal Biochem 1996;242:31-39
15. Stables J, Mattheakis LC, Chang R, Rees S. Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells. Methods Enzymol 2000;327:456-471
16. Nayak TK, Harinath S, Nama S, et al. Inhibition of human two pore domain K+ channel TREK1 by local anesthetic Lidocaine: negative cooperativity and half-of-sites saturation kinetics. Mol Pharmacol 2009;76:903-917
17. Triggle D. Voltage gated ion channels as drug targets, John Wiley & Sons, 2006
18. Diwan JJ, Paliwal R, Kaftan E, Bawa R. Amitochondrial protein fraction catalyzing transport of the K+ analog Tl+. FEBS Lett 1990;273:215-218
19. Weaver CD, Harden D, Dworetzky SI, et al. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modultaors in mammalian cells. J Biomol Screen 2004;9:671-677
20. Bartschat DK, Blaustein MP. Potassium channels in isolated presynaptic nerve terminals from Rat Brain. J Physiol 1985;361:419-440
21. Scott CW, Wilkins DE, Trivedi S, Crankshaw DJ. A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectroscopy. Anal Biochem 2003;319:251-257
22. Trivedi S, Dekermendjian K, Julien R, et al. Cellular HTS assays for pharmacological characterization of NaV1.7 modulators. Assay Drug Dev Technol 2007;6(2):167-179
23. Terstappen GC. Functional analysis of native and recombinant ion channels using high-capacity nonradioactive rubidium efflux assay. Anal Biochem 1999;272:149-155
24. Gill S, Gill R, Wicks D, Liang D. A cell based Rb flux assa of the KV1.3 potassium channel. Assay Drug Dev Technol 2007;5(3):373-380
25. Sorota S, Zhang X, Margulis M, et al. Characterization of a hERG screen using the ionworks HTS: comparison of a hERG rubidium efflux screen. Assay Drug Dev Technol 2005;3(1):47-57
26. Wang K, Mcllvain B, Tseng E, et al. Validation of an atomic absorption rubidium ion efflux assa for KCNQ/M channels using Io channel reader 8000. Assay Drug Dev Technol 2004;2(5):525-534
27. Jow F, Tseng E, Maddox T, et al. Rb efflux through functional activation of cardiac KCNQ/minK chanels by the Benzodiazepine R-L3 (L-364,373). Assay Drug Dev Technol 2006;4:443-450
28. Rezazadeh S, Hesketh JC, Fedida D. Rb flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high throughput Rb efflux assay. J Biomol screen 2004;9(7):588-597
29. Foster CD, Speakman MJ, Fujii K, Brading AF. The effects of cromakalim on the detrusor muscle of human and pig urinary bladder. Br J Pharmacol 1989;97:281-291 (Pubitemid 19113973)
30. Baxter DF, Kirk M, Garcia AF, et al. A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen 2002;7:79-85
31. Minta A, Tsien RY. Fluorescent indicators for cytosolic sodium. J Biol Chem 1989;264:19449-19457
32. Wolff C, Fuks B, Chatelain P. Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays. J Biomol Screen 2003;8:533-543
33. Gonzalez JE, Tsien RY. Improved indicators of cell membrane potential that use fluorescence resonance energy transfer. Chem Biol 1997;4:269-277
34. Gonzalez JE, Oades K, Leychkis Y, et al. Cellbased assays and instrumentation for screening ion-channel targets. Drug Discov Today 1999;4:431-439
35. Huang CJ, Harootunian A, Maher MP, et al. Characterization of voltage-gated sodium channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol 2006;24:439-446
36. Dunlop J, Bowlby M, Peri R, et al. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov 2008;7:358-368
37. Farrea C, Georgea M, Bruggemanna A, Fertig N. Ion channel screening-automated patch clamp on the rise. Drug Discov Today Technol 2008;5(1):e23-8
38. Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a bayesian model. J Med Chem 2004;47:4463-4470
39. Ghose AK, Viswanadhan VN, Wendoloski J. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J Phys Chem 1998;102:3762-3772
40. Rogers D, Brown RD, Hahn M. Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 2005;10:682-686